Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.
Company profile
Ticker
KLTO, KLTOW
Exchange
Website
CEO
Dr. Joseph Sinkule Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Redwoods Acquisition Corp.
SEC CIK
Corporate docs
IRS number
862727441
KLTO stock data
Latest filings (excl ownership)
8-K
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development
2 Oct 24
424B3
Prospectus supplement
1 Oct 24
EFFECT
Notice of effectiveness
19 Sep 24
S-1/A
IPO registration (amended)
12 Sep 24
S-1
IPO registration
5 Sep 24
8-K
Departure of Directors or Certain Officers
30 Aug 24
8-K
Departure of Directors or Certain Officers
21 Aug 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Aug 24
10-Q
2024 Q2
Quarterly report
19 Aug 24
NT 10-Q
Notice of late quarterly filing
14 Aug 24
Latest ownership filings
4
KERRY PROPPER
2 Jul 24
3
KERRY PROPPER
1 Jul 24
SC 13G
CHARDAN CAPITAL MARKETS LLC
27 Jun 24
SC 13G/A
Shaolin Capital Management LLC
22 Feb 24
SC 13G/A
MMCAP International Inc. SPC
13 Feb 24
SC 13G/A
MMCAP International Inc. SPC
14 Feb 23
SC 13G
Shaolin Capital Management LLC
13 Feb 23
SC 13G/A
Space Summit Capital LLC
8 Feb 23
SC 13G/A
Feis Lawrence
9 Jan 23
4
Change in insider ownership
11 Apr 22
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 845.34 k | 845.34 k | 845.34 k | 845.34 k | 845.34 k | 845.34 k |
Cash burn (monthly) | (no burn) | (no burn) | 150.55 k | 117.63 k | 184.29 k | 160.55 k |
Cash used (since last report) | n/a | n/a | 550.87 k | 430.43 k | 674.34 k | 587.49 k |
Cash remaining | n/a | n/a | 294.46 k | 414.91 k | 171.00 k | 257.85 k |
Runway (months of cash) | n/a | n/a | 2.0 | 3.5 | 0.9 | 1.6 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 24 | Chardan Capital Markets | Common Stock | Sell | Dispose S | No | No | 2.0469 | 180,000 | 368.44 k | 1,284,364 |
1 Jul 24 | Chardan Capital Markets | Common Stock | Sell | Dispose S | No | No | 2.0638 | 115,136 | 237.62 k | 1,464,364 |
28 Jun 24 | Chardan Capital Markets | Common Stock | Sell | Dispose S | No | No | 2.5341 | 47,000 | 119.10 k | 1,579,500 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Oct 24
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
17 Oct 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
16 Oct 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
16 Oct 24
Klotho Neurosciences Tapped Peter Moriarty Of Shire Pharma As COO
15 Oct 24
Press releases
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
15 Oct 24
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
29 Sep 24
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
17 Sep 24
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
4 Sep 24
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
26 Aug 24